VINCRISTINE SULFATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for vincristine sulfate and what is the scope of patent protection?
Vincristine sulfate
is the generic ingredient in six branded drugs marketed by Acrotech, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.There are eight drug master file entries for vincristine sulfate. One supplier is listed for this compound.
Summary for VINCRISTINE SULFATE
| US Patents: | 0 |
| Tradenames: | 6 |
| Applicants: | 9 |
| NDAs: | 13 |
| Drug Master File Entries: | 8 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 46 |
| Clinical Trials: | 478 |
| Patent Applications: | 7,462 |
| What excipients (inactive ingredients) are in VINCRISTINE SULFATE? | VINCRISTINE SULFATE excipients list |
| DailyMed Link: | VINCRISTINE SULFATE at DailyMed |
Recent Clinical Trials for VINCRISTINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 1 |
| University of Colorado, Denver | Phase 1 |
| Boston Children's Hospital | Phase 1 |
Pharmacology for VINCRISTINE SULFATE
| Drug Class | Vinca Alkaloid |
Medical Subject Heading (MeSH) Categories for VINCRISTINE SULFATE
Anatomical Therapeutic Chemical (ATC) Classes for VINCRISTINE SULFATE
US Patents and Regulatory Information for VINCRISTINE SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | VINCRISTINE SULFATE | vincristine sulfate | INJECTABLE;INJECTION | 071559-001 | Apr 11, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | VINCRISTINE SULFATE | vincristine sulfate | INJECTABLE;INJECTION | 071561-001 | Apr 11, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | VINCRISTINE SULFATE | vincristine sulfate | INJECTABLE;INJECTION | 076296-001 | Dec 20, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa | VINCRISTINE SULFATE PFS | vincristine sulfate | INJECTABLE;INJECTION | 075493-001 | Sep 1, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VINCREX | vincristine sulfate | INJECTABLE;INJECTION | 070867-001 | Jul 12, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VINCRISTINE SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-003 | Mar 7, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
